Cloud DX Reveals EXtended Reality  Division to Bring to Market Award-Winning, Patented Metaverse Application

Cloud DX Reveals EXtended Reality Division to Bring to Market Award-Winning, Patented Metaverse Application

Cloud XR's Virtual Clinician Assistant™ offers healthcare teams an immersive and real-time augmented clinical experience, ripe for the evolving Medical Metaverse.

News in Summary

  • In its commitment to medical innovation, Cloud DX publicly unveils its Cloud XR division, after 6 years of development, to support the Medical Metaverse with its 3D holographic eXtended reality experience
  • The next iteration of this ground-breaking innovation combines the patented, award-winning VITALITI™ vital sign monitor with Microsoft's Hololens 2 or Apple's AR application along with additional integration to hospital record systems.

Cloud DX Inc. (the "Company" or "Cloud DX") (TSXV:CDX) (OTC:CDXFF), is pleased to announce the launch of its Cloud XR division as the company pursues opportunities to deliver its Virtual Clinician Assistant in an eXtended Reality platform consisting of Cloud DX's VITALITI™ continuous vital sign monitor and Connected Health software platform to render realistic 3D holographic images. This digital experience runs on Microsoft's Hololens 2 headset or through the Apple AR application. Together, this futuristic system is designed serve as a fully functioning cornerstone of the new Medical Metaverse

In October 2021, Facebook CEO Mark Zuckerberg announced that his iconic company's name would change to "Meta", an acknowledgment that the concept of the Metaverse had reached critical mass. Applications that provide real and concrete benefits in the Metaverse are gaining attention worldwide - especially those that intersect with health care.

The Cloud XR division will work with current and emerging partners to complete, test, and launch a fully 3D holographic hardware and software solution that had been in development by Cloud DX and Sheridan Center for Mobile Innovation since 2016.

This Metaverse application will allow clinicians to view 3D holographic representations of a patient's body, real-time vital sign readings, diagnostic images, and other data from their Electronic Medical Record (EMR). The Hololens 2 user interface (UI) allows clinicians to either view cutaway 3D representations of patients physically in front of them, or a patient located anywhere in the world with a 3D holographic "body" floating in space. Users can control the application with a combination of voice commands and hand gestures.

Real time data on all main vital signs are gathered by the Company's proprietary VITALITI™ continuous vital sign monitor, a patented and patent-pending system that collects heart rate, pulse rate variability, respiration, core body temperature, 5-lead ECG signals, blood oxygen saturation and most importantly, continuous non-invasive blood pressure.

The Cloud XR application is set to be integrated to a hospital's EMR system, allowing clinicians instant touch-free access to diagnostic images (x-rays, CT scans), medication records, charts, notes and other key data. Likewise, the voice command system allows doctors to dictate notes, order medications, and practice Metaverse medicine completely hands-free.

Cloud DX eXtended Reality is protected by two granted US patents, with additional patents pending in Canada, China, the European Union, and Australia.

VITALITI™ by Cloud DX has received multiple prestigious awards, including the first-ever XPRIZE Bold Epic Innovator Award, Fast Company magazine "World Changing Idea" finalist, MEDy Award for Convergence from Exponential Medicine, a 2021 Edison Award and is co-winner of the National Sciences and Engineering Research Council of Canada's 2021 Synergy Award along with Sheridan College, specifically for the eXtended Reality system.

An early iteration of the Cloud XR platform was displayed at a Singularity University event in Toronto in 2017 where it was featured in a Discovery Channel TV episode.

Applications for the eXtended Reality platform include touchless, hands-free interaction with patients vulnerable to infection, remote examination and treatment of patients by clinicians in any location, and the ability of multiple clinicians to consult on an examination of a patient from different locations. Cloud DX believes its Virtual Clinician Assistant is the most full-featured innovation currently under development for the Medical Metaverse.

"We began working with Cloud DX on the Clinic of the Future project in 2016, and together we have created a fully functioning platform with many real-life benefits for both patients and clinicians, especially as we emerge from the global pandemic," said Dr. Edward Sykes, Director, Sheridan Center for Mobile Innovation "I'm extremely excited to see Cloud DX commit to the next stage of testing and initial deployment of the VITALITI and Hololens 2 combination".

"After six years of intensive work, we are ready to show the world our cutting-edge eXtended Reality platform - at a moment in time when the delivery of services in a fully virtual Metaverse is becoming the clear direction that many technologies are heading," said Robert Kaul, CEO and Founder of Cloud DX "Once again, Cloud DX has showcased its ability to be on the forefront of innovation, with an integrated system that extends our mission to make health care better for everyone."


ABOUT Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers". In 2021, Cloud DX became an exclusive partner of Medtronic Canada.

Cloud DX Investor Sitehttps://ir.clouddx.com/overview/default.aspx

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Social Links

Twitter: https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:
Janine Scott
Marketing Lead
888-543-0944
janine.scott@clouddx.com

For investor inquiries please contact:
Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@clouddx.com

SOURCE: Cloud DX Inc.



View source version on accesswire.com:
https://www.accesswire.com/687102/Cloud-DX-Reveals-EXtended-Reality-XR-Division-to-Bring-to-Market-Award-Winning-Patented-Metaverse-Application

News Provided by ACCESSWIRE via QuoteMedia

CDX:CA
The Conversation (0)
Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Cloud DX partners with Sheridan College on Medical Metaverse Research and Development

Developing the Clinic of the Future, Cloud DX work to be supported by Sheridan College through federal grant

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX Signs Contract with Paramedical Service Provider for Remote Patient Monitoring

Cloud DX chosen as Virtual Care Platform for the Ontario Paramedical Service provider, replacing existing hardware and services

Cloud DX (TSXV:CDX)(OTCQX:CDXFF) is pleased to announce a new 24-month contract with an Ontario Paramedic Service Provider enabling the client to provide Remote Patient Monitoring (RPM) across its serviceable area. Cloud DX will provide its award-winning Connected Health™ platform and support the client as it transitions from its previous remote care tools to Cloud DX's Virtual Care Platform. The client showcases how beneficial ‘Remote Care Monitoring' is for Paramedical Service providers, enabling providers to establish deeper community roots and maintain funding levels, while community members benefit from greater access to much-needed care. The client has purchased 223 Connected Health™ kits totalling ~$145,000 CAD with additional recurring fees for subscription software services. Funding for the program comes from the $82.5M Community Paramedicine for Long-Term Care program announced by the Ontario government on October 22, 2021

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs Two Contracts with US Primary Care Clinics

Cloud DX Signs Two Contracts with US Primary Care Clinics

Continued growth in US RPM as partner Maxwell Telecare signs two additional clinics in Illinois

News in Summary

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Cloud DX Signs New Palliative Contract with Ontario Healthcare Team

Healthcare team to use Connected Health™ kits to provide dignity in care for up to 85 patients

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Cloud DX Announces Closing of Private Placement

Cloud DX Announces Closing of Private Placement

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), a leading North American provider of virtual care and Remote Patient Monitoring (RPM) solutions, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 260 units (the "Units") of the Corporation at a price of $1,000 per Unit, for gross proceeds of $260,000 (the "Offering"). Each Unit is comprised of (i) a C$1,000 principal amount unsecured convertible debenture (each, a "Debenture") and (ii) 1,430 common share purchase warrants of the Corporation (each, a "Warrant"). The Debentures will mature on January 27, 2025 (the "Maturity Date") and shall bear interest at a simple rate of 10% per annum. The principal amount of the Debentures may be converted at the election of the holder thereof into common shares in the capital of the Company ("Common Shares") at a conversion price of C$0.35 per Common Share (the "Conversion Price") at any time prior to the Maturity Date. Each Warrant entitles the holder thereof to acquire one common share of the Corporation (each, a "Common Share") at a price of C$0.50 per Common Share at any time prior to 4:30 p.m. (Toronto Time) on January 27, 2024

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

(TheNewswire)

Ocumetics Technology Corp.

Calgary, Alberta May 24, 2024 - TheNewswire .  Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Robot hand touching human hand with a spark in between.

Top 10 Emerging Technologies to Watch in 2024

Even as global economic challenges have disrupted businesses in recent years, companies continue to look for new opportunities in emerging technologies and for innovations that can reshape the world.

In its Top 10 Strategic Technology Trends for 2024 report, research and consulting firm Gartner examines the tech innovations its analysts believe will have the greatest impact on how successful businesses are in maintaining a positive financial position and operational excellence in the era of digital transformation. The report includes a list of the top emerging technologies to watch, and Gartner indicates that they could be key to sustainable enterprise growth.

A major theme in the report is the rise of technologies that will help businesses address three key priorities: protecting and preserving past and future investments, building the right solutions for the right stakeholders at the right time and delivering value for the changing environments of both internal and external customers.

Keep reading...Show less
E-Power Resources Inc to Participate in THE Mining Investment Event of the North, Canada's Only Tier I Global Mining Investment Conference

E-Power Resources Inc to Participate in THE Mining Investment Event of the North, Canada's Only Tier I Global Mining Investment Conference

E-Power Resources Inc (CSE: EPR) is pleased to announce that it will be participating in THE Mining Investment Event of the North, ("THE Event") taking place June 4-6, 2024 in Quebec City at the Centre des congrès de Québec.

Management from E-Power Resources Inc will be holding one-on-one investor meetings throughout the three-day conference.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a productive translational research group at Dalhousie University and has successfully initiated two clinical trials in cancer immunotherapy. He is widely published in the field of cancer immunobiology and immunotherapy research, and a recognized innovator in the field of intra-tumoral cancer immunotherapy. Dr. Giacomantonio currently serves on Sona's Advisory Board and is the Principal Investigator for Sona's pre-clinical studies using Sona's gold nanorods in its Targeted Hyperthermia Therapy ("THT") for triple negative breast cancer, melanoma, and colorectal cancer. Sona is extremely excited to have Dr. Giacomantonio's vision and experience to lead the development of our THT-based immunotherapy towards first-in-human clinical trials.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nanalysis Announces First Quarter 2024 Conference Call

Hosting Call at 5:00 pm ET on Wednesday , May 29th

European Q&A Session on Thursday May 30th at 8:30am ET

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

(TheNewswire)

Calgary, Alberta TheNewswire - May 15, 2024. Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the " Principal "). The debentures will be subject to an original issue discount of 6%, resulting in net available funds to the Corporation of up to $3,760,000 (the " Net Proceeds "). Debentures will bear interest at rate of 18% per annum, compounded annually. The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue. The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×